SHARE
Cancer Immunotherapy Market

Cancer Immunotherapy Market Forecasts to 2028 – Global Analysis By Application (Blood Cancers, Ovarian Cancer, Pancreatic Cancer, Liver Cancer), End User (Hospitals & Clinics, Ambulatory Surgical Centres) and By Geography

4.4 (21 reviews)
Published: February 2022 ID: SMRC20376
4.4 (21 reviews)
Published: February 2022 ID: SMRC20376

This report covers the impact of COVID-19 on this global market
Loading...

According to Stratistics MRC, the Global Cancer Immunotherapy Market is accounted for $119.39 billion in 2021 and is expected to reach $337.42 billion by 2028 growing at a CAGR of 16.0% during the forecast period. Cancer immunotherapy is a cancer treatment that enhances the immune system's ability to fight cancer. This therapy is preferable than the old technique because it provides long-term cancer protection, has less side effects, and treats a wider range of cancers.

Market Dynamics:

Driver:

Growing adoption of immunotherapy


The treatment options for cancer, such as chemotherapies and radiation therapy, although have more side effects, are more widely used as compared to immunotherapies. While they can effectively kill or remove cancer cells, the use of these treatments is often limited because they tend to destroy healthy cells in large numbers as well. As immunotherapies involve the mechanism of enhancing the body’s own immunity using man-made proteins such as monoclonal antibodies, they are accepted worldwide over other treatment options.

Restraint:

High product developmental cost


The cost of developing new products for cancer immunotherapy is on the higher side. Due to this, there is a negative impact on the growth of the market.

Opportunity:

Technological developments


The developments in technology and surge in healthcare expenditure positively affect the cancer immunotherapy market. Furthermore, increase in clinical trials against several types of cancers in immunotherapy extends profitable opportunities to the market players in the forecast period.

Threat:

Stringent government regulations


The stringent regulations related to cancer immunotherapy are anticipated to be a major threat for the growth of the cancer immunotherapy market. Government have better supervision over the use of immunotherapy and is also taking care of the clinical trials going on user the government norms, which has made it difficult to the companies to enter the industry and is hence expected to hinder the growth of the market.

The hospitals & clinics segment is expected to be the largest during the forecast period

Hospitals and clinics remain the most favoured medical settings, as these institutions are equipped with advanced facilities to allow for effective diagnosis and treatment. High adoption of advanced diagnostics and treatment equipment, as well as therapeutics, supported by public and private funding, further improves the healthcare quality offered by hospitals. Relatively short wait times and ease of getting appointments are projected to widen the patient base opting for clinic-based healthcare. Progressive growth in the demand for quality cancer therapeutics in clinics is influencing clinicians to focus on offering cancer immunotherapy to patients, which is driving the exponential adoption of cancer therapeutics in clinics.

The monoclonal antibodies segment is expected to have the highest CAGR during the forecast period

Monoclonal antibody based drugs assist in flagging cancer cells, trigger cell-membrane destruction, inhibiting malignant cell proliferation, preventing blood vessel growth, easy chemotherapy delivery and binding cancer and immune cells among other benefits. Their ability to trigger an antitumor immune response makes them highly sought after.

Region with largest share:

North America is projected to hold the largest market share owing to the favourable dynamics, such as progressive improvements in healthcare infrastructure and government initiatives underpinning the R&D activities of players. The rising number of patients suffering from cancer, increasing adoption rate of immunotherapy, and development of bioinformatics tools are enhancing the drug development process also contribute towards the market growth. 

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR due to the increasing ageing population, altering lifestyles and socio-economic changes. Consequently, healthcare spending to develop advanced research & development facilities for designing high-grade oncology diagnostics are taking place, a factor which is expected to fuel cancer immunotherapy market growth.

Key players in the market

Some of the key players profiled in the Cancer Immunotherapy Market include Merck & Co., Inc., Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Bristol-Myers Squibb, ELI Lilly and Company, Dr. Reddy's Laboratories Ltd, Astrazeneca, Amgen Inc., Lupin Limited, Bausch Health Companies Inc., Celgene Corporation, Apotex Inc, Immunomedics Inc, and Hikma Pharmaceutical PLC.

Key developments:

In September 2021: Amgen Plc. announced its first combination study results from its Phase 1b/2 CodeBreaK 101 study, a comprehensive global clinical development program in patients with KRAS G12C-mutated advanced colorectal cancer. It shows that combining LUMAKRASTM (sotorasib) with Vectibix® (panitumumab) demonstrate efficacy and safety.

In September 2021: Bristol-Myers Squibb Company conducted a survey that included 250 oncologists, surgeons and specialists from countries like U.S., Germany and Japan. The survey revealed the potential immunotherapy carries for cancers that are detected at an early stage.

Products Covered:
• Cytokines & Immunomodulators
• Adoptive Cell Transfer
• Vaccines
• Monoclonal Antibodies
• Cell Therapies
• Checkpoint Inhibitors

Applications Covered:
• Blood Cancers
• Ovarian Cancer
• Pancreatic Cancer
• Liver Cancer
• Breast Cancer
• Melanoma
• Lung Cancer
• Gastric Cancer (Stomach Cancer)
• Cervical Cancer 
• Prostate Cancer
• Multiple Myeloma
• Head & Neck Cancer
• Colorectal Cancer
• Other Applications

End Users Covered:
• Hospitals & Clinics
• Ambulatory Surgical Centres
• Cancer Research Centers

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan       
o China       
o India       
o Australia 
o New Zealand
o South Korea
o Rest of Asia Pacific   
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary      
        
2 Preface        

 2.1 Abstract      
 2.2 Stake Holders     
 2.3 Research Scope     
 2.4 Research Methodology    
  2.4.1 Data Mining    
  2.4.2 Data Analysis    
  2.4.3 Data Validation    
  2.4.4 Research Approach    
 2.5 Research Sources     
  2.5.1 Primary Research Sources   
  2.5.2 Secondary Research Sources   
  2.5.3 Assumptions    
        
3 Market Trend Analysis     
 3.1 Introduction     
 3.2 Drivers      
 3.3 Restraints      
 3.4 Opportunities     
 3.5 Threats      
 3.6 Product Analysis     
 3.7 Application Analysis     
 3.8 End User Analysis     
 3.9 Emerging Markets     
 3.10 Impact of Covid-19     
        
4 Porters Five Force Analysis     
 4.1 Bargaining power of suppliers    
 4.2 Bargaining power of buyers    
 4.3 Threat of substitutes     
 4.4 Threat of new entrants    
 4.5 Competitive rivalry     
        
5 Global Cancer Immunotherapy Market, By Product   
 5.1 Introduction     
 5.2 Cytokines & Immunomodulators   
  5.2.1 Granulocyte-Macrophage Colony-Stimulating Factor (Gm-Csf & G-Csf)
  5.2.2 Interleukins (IL)    
  5.2.3 Interferons (IFN)    
  5.2.4 Oncolytic Virus    
   5.2.4.1 Immunity as an Ally   
   5.2.4.2 Immunity as an Obstacle  
   5.2.4.3 Approved Products & Clinical Trails 
   5.2.4.4 Immunotherapy/Non-Specific Immunotherapies
 5.3 Adoptive Cell Transfer    
 5.4 Vaccines      
  5.4.1 Therapeutic Vaccines   
  5.4.2 Prophylactic Vaccines   
 5.5 Monoclonal Antibodies    
  5.5.1 Conjugated Monoclonal Antibodies  
  5.5.2 Naked Monoclonal Antibodies   
  5.5.3 Bispecific Monoclonal Antibodies  
 5.6 Cell Therapies     
  5.6.1 Dendritic Cells    
  5.6.2 Chimeric Antigen Receptor (CAR) T Cell Therapy 
 5.7 Checkpoint Inhibitors    
  5.7.1 Programmed Death 1 (PD-1) & Programmed Death Ligand 1 (PD-L1)
  5.7.2 Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4)
        
6 Global Cancer Immunotherapy Market, By Application  

 6.1 Introduction     
 6.2 Blood Cancers     
 6.3 Ovarian Cancer     
 6.4 Pancreatic Cancer     
 6.5 Liver Cancer     
 6.6 Breast Cancer     
 6.7 Melanoma     
 6.8 Lung Cancer     
 6.9 Gastric Cancer (Stomach Cancer)   
 6.10 Cervical Cancer       
 6.11 Prostate Cancer     
 6.12 Multiple Myeloma     
 6.13 Head & Neck Cancer     
 6.14 Colorectal Cancer     
 6.15 Other Applications     
  6.15.1 Lymphoma    
  6.15.2 Renal Cell Carcinoma   
        
7 Global Cancer Immunotherapy Market, By End User   
 7.1 Introduction     
 7.2 Hospitals & Clinics     
 7.3 Ambulatory Surgical Centres    
 7.4 Cancer Research Centers    
        
8 Global Cancer Immunotherapy Market, By Geography  
 8.1 Introduction     
 8.2 North America     
  8.2.1 US     
  8.2.2 Canada     
  8.2.3 Mexico     
 8.3 Europe      
  8.3.1 Germany     
  8.3.2 UK     
  8.3.3 Italy     
  8.3.4 France     
  8.3.5 Spain     
  8.3.6 Rest of Europe    
 8.4 Asia Pacific     
  8.4.1 Japan     
  8.4.2 China     
  8.4.3 India     
  8.4.4 Australia     
  8.4.5 New Zealand     
  8.4.6 South Korea    
  8.4.7 Rest of Asia Pacific    
 8.5 South America     
  8.5.1 Argentina     
  8.5.2 Brazil     
  8.5.3 Chile     
  8.5.4 Rest of South America   
 8.6 Middle East & Africa     
  8.6.1 Saudi Arabia    
  8.6.2 UAE     
  8.6.3 Qatar     
  8.6.4 South Africa    
  8.6.5 Rest of Middle East & Africa   
        
9 Key Developments      
 9.1 Agreements, Partnerships, Collaborations and Joint Ventures 
 9.2 Acquisitions & Mergers    
 9.3 New Product Launch      
 9.4 Expansions     
 9.5 Other Key Strategies     
        
10 Company Profiling      
 10.1 Merck & Co., Inc.     
 10.2 Bayer AG      
 10.3 F. Hoffmann-La Roche Ltd    
 10.4 GlaxoSmithKline Plc     
 10.5 Bristol-Myers Squibb     
 10.6 ELI Lilly and Company    
 10.7 Dr. Reddy's Laboratories Ltd    
 10.8 Astrazeneca     
 10.9 Amgen Inc.     
 10.10 Lupin Limited     
 10.11 Bausch Health Companies Inc.    
 10.12 Celgene Corporation     
 10.13 Apotex Inc     
 10.14 Immunomedics Inc     
 10.15 Hikma Pharmaceutical PLC    


List of Tables       
1 Global Cancer Immunotherapy Market Outlook, By Region (2020-2028) ($MN)
2 Global Cancer Immunotherapy Market Outlook, By Product (2020-2028) ($MN)
3 Global Cancer Immunotherapy Market Outlook, By Cytokines & Immunomodulators (2020-2028) ($MN)
4 Global Cancer Immunotherapy Market Outlook, By Granulocyte-Macrophage Colony-Stimulating Factor (Gm-Csf & G-Csf) (2020-2028) ($MN)
5 Global Cancer Immunotherapy Market Outlook, By Interleukins (IL) (2020-2028) ($MN)
6 Global Cancer Immunotherapy Market Outlook, By Interferons (IFN) (2020-2028) ($MN)
7 Global Cancer Immunotherapy Market Outlook, By Oncolytic Virus (2020-2028) ($MN)
8 Global Cancer Immunotherapy Market Outlook, By Adoptive Cell Transfer (2020-2028) ($MN)
9 Global Cancer Immunotherapy Market Outlook, By Vaccines (2020-2028) ($MN)
10 Global Cancer Immunotherapy Market Outlook, By Therapeutic Vaccines (2020-2028) ($MN)
11 Global Cancer Immunotherapy Market Outlook, By Prophylactic Vaccines (2020-2028) ($MN)
12 Global Cancer Immunotherapy Market Outlook, By Monoclonal Antibodies (2020-2028) ($MN)
13 Global Cancer Immunotherapy Market Outlook, By Conjugated Monoclonal Antibodies (2020-2028) ($MN)
14 Global Cancer Immunotherapy Market Outlook, By Naked Monoclonal Antibodies (2020-2028) ($MN)
15 Global Cancer Immunotherapy Market Outlook, By Bispecific Monoclonal Antibodies (2020-2028) ($MN)
16 Global Cancer Immunotherapy Market Outlook, By Cell Therapies (2020-2028) ($MN)
17 Global Cancer Immunotherapy Market Outlook, By Dendritic Cells (2020-2028) ($MN)
18 Global Cancer Immunotherapy Market Outlook, By Chimeric Antigen Receptor (CAR) T Cell Therapy (2020-2028) ($MN)
19 Global Cancer Immunotherapy Market Outlook, By Checkpoint Inhibitors (2020-2028) ($MN)
20 Global Cancer Immunotherapy Market Outlook, By Programmed Death 1 (PD-1) & Programmed Death Ligand 1 (PD-L1) (2020-2028) ($MN)
21 Global Cancer Immunotherapy Market Outlook, By Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4) (2020-2028) ($MN)
22 Global Cancer Immunotherapy Market Outlook, By Application (2020-2028) ($MN)
23 Global Cancer Immunotherapy Market Outlook, By Blood Cancers (2020-2028) ($MN)
24 Global Cancer Immunotherapy Market Outlook, By Ovarian Cancer (2020-2028) ($MN)
25 Global Cancer Immunotherapy Market Outlook, By Pancreatic Cancer (2020-2028) ($MN)
26 Global Cancer Immunotherapy Market Outlook, By Liver Cancer (2020-2028) ($MN)
27 Global Cancer Immunotherapy Market Outlook, By Breast Cancer (2020-2028) ($MN)
28 Global Cancer Immunotherapy Market Outlook, By Melanoma (2020-2028) ($MN)
29 Global Cancer Immunotherapy Market Outlook, By Lung Cancer (2020-2028) ($MN)
30 Global Cancer Immunotherapy Market Outlook, By Gastric Cancer (Stomach Cancer) (2020-2028) ($MN)
31 Global Cancer Immunotherapy Market Outlook, By Cervical Cancer (2020-2028) ($MN)
32 Global Cancer Immunotherapy Market Outlook, By Prostate Cancer (2020-2028) ($MN)
33 Global Cancer Immunotherapy Market Outlook, By Multiple Myeloma (2020-2028) ($MN)
34 Global Cancer Immunotherapy Market Outlook, By Head & Neck Cancer (2020-2028) ($MN)
35 Global Cancer Immunotherapy Market Outlook, By Colorectal Cancer (2020-2028) ($MN)
36 Global Cancer Immunotherapy Market Outlook, By Other Applications (2020-2028) ($MN)
37 Global Cancer Immunotherapy Market Outlook, By Lymphoma (2020-2028) ($MN)
38 Global Cancer Immunotherapy Market Outlook, By Renal Cell Carcinoma (2020-2028) ($MN)
39 Global Cancer Immunotherapy Market Outlook, By End User (2020-2028) ($MN)
40 Global Cancer Immunotherapy Market Outlook, By Hospitals & Clinics (2020-2028) ($MN)
41 Global Cancer Immunotherapy Market Outlook, By Ambulatory Surgical Centres (2020-2028) ($MN)
42 Global Cancer Immunotherapy Market Outlook, By Cancer Research Centers (2020-2028) ($MN)
        
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.

Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.

All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

We have 3 different licensing options available in electronic format.

  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.

All our reports are typically be emailed to you as an attachment.

To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.

We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

Select License Type

Allows one person to have access to the ordered product.The ordered product cannot be distributed to anyone else.
Allows the ordered product to be shared among a maximum of 5 people within your organisation.
Allows the product to be shared among all employees of your organisation at one particular location.
Allows the product to be shared among all employees of your organisation regardless of their geographical location.

WHY CHOOSE US ?

Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials